Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine

A woman with nocturnal eating syndrome responsive to dexfenfluramine (DXF) is reported. Eating consisted of nightly ingestion of large amounts of high-calorie meals and often sloppy meal consumption or preparation. Amnesia for the episodes was total. Anorexigenic medications produced partial control of her daytime carbohydrate craving and no nocturnal eating change. DXF stopped her eating behavior completely. Nocturnal eating herein meets all 4 DSM-III-R diagnostic criteria for binge eating disorder. 5-HT role in neural process controlling sleep-wakefulness (SW) has been widely shown. A 5-HT agonist like DXF could determine changes in the SW processes producing the therapeutic outcome reported herein. However, a specific DXF effect on the behavioral control of carbohydrate ingestion can not be dismissed.

Saved in:
Bibliographic Details
Main Authors: Mancini,Marcio C., Alóe,Flávio
Format: Digital revista
Language:English
Published: Associação Paulista de Medicina - APM 1994
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31801994000200011
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-31801994000200011
record_format ojs
spelling oai:scielo:S1516-318019940002000112009-07-03Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramineMancini,Marcio C.Alóe,Flávio Nocturnal eating syndrome dexfenfluramine serotonin binge eating disorder A woman with nocturnal eating syndrome responsive to dexfenfluramine (DXF) is reported. Eating consisted of nightly ingestion of large amounts of high-calorie meals and often sloppy meal consumption or preparation. Amnesia for the episodes was total. Anorexigenic medications produced partial control of her daytime carbohydrate craving and no nocturnal eating change. DXF stopped her eating behavior completely. Nocturnal eating herein meets all 4 DSM-III-R diagnostic criteria for binge eating disorder. 5-HT role in neural process controlling sleep-wakefulness (SW) has been widely shown. A 5-HT agonist like DXF could determine changes in the SW processes producing the therapeutic outcome reported herein. However, a specific DXF effect on the behavioral control of carbohydrate ingestion can not be dismissed.info:eu-repo/semantics/openAccessAssociação Paulista de Medicina - APMSao Paulo Medical Journal v.112 n.2 19941994-06-01info:eu-repo/semantics/reporttext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31801994000200011en10.1590/S1516-31801994000200011
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Mancini,Marcio C.
Alóe,Flávio
spellingShingle Mancini,Marcio C.
Alóe,Flávio
Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine
author_facet Mancini,Marcio C.
Alóe,Flávio
author_sort Mancini,Marcio C.
title Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine
title_short Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine
title_full Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine
title_fullStr Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine
title_full_unstemmed Nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine
title_sort nocturnal eating syndrome: a case report with therapeutic response to dexfenfluramine
description A woman with nocturnal eating syndrome responsive to dexfenfluramine (DXF) is reported. Eating consisted of nightly ingestion of large amounts of high-calorie meals and often sloppy meal consumption or preparation. Amnesia for the episodes was total. Anorexigenic medications produced partial control of her daytime carbohydrate craving and no nocturnal eating change. DXF stopped her eating behavior completely. Nocturnal eating herein meets all 4 DSM-III-R diagnostic criteria for binge eating disorder. 5-HT role in neural process controlling sleep-wakefulness (SW) has been widely shown. A 5-HT agonist like DXF could determine changes in the SW processes producing the therapeutic outcome reported herein. However, a specific DXF effect on the behavioral control of carbohydrate ingestion can not be dismissed.
publisher Associação Paulista de Medicina - APM
publishDate 1994
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31801994000200011
work_keys_str_mv AT mancinimarcioc nocturnaleatingsyndromeacasereportwiththerapeuticresponsetodexfenfluramine
AT aloeflavio nocturnaleatingsyndromeacasereportwiththerapeuticresponsetodexfenfluramine
_version_ 1756421402280329216